Get the Stockscreener App
4.685
1.16%
-0.055
Trisalus Life Sciences Inc stock is traded at $4.685, with a volume of 38,411.
It is down -1.16% in the last 24 hours and up +1.41% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$4.74
Open:
$4.75
24h Volume:
38,411
Relative Volume:
0.32
Market Cap:
$233.63M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-2.6738
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
-6.67%
1M Performance:
+1.41%
6M Performance:
-8.32%
1Y Performance:
+16.83%
1-Day Range:
$4.5001
$4.78
1-Week Range:
$4.5001
$5.0994
52-Week Range:
$3.42
$5.88
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.685 | 236.37M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
123.49 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.88 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
359.38 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.87 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
What machine learning models say about TriSalus Life Sciences Inc.July 2025 Gainers & Stepwise Trade Signal Implementation - newser.com
Automated trading signals detected on TriSalus Life Sciences Inc.Volume Spike & Fast Exit Strategy with Risk Control - newser.com
Has TriSalus Life Sciences Inc. formed a bullish divergenceStock Surge & Reliable Price Breakout Signals - newser.com
Is TriSalus Life Sciences Inc. Equity Warrant still worth holding after the dip2025 Key Lessons & Smart Money Movement Tracker - newser.com
Is TriSalus Life Sciences Inc. stock a dividend growth opportunityJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Real time social sentiment graph for TriSalus Life Sciences Inc.2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
TriSalus Life Sciences Inc. Equity Warrant stock volume spike explainedBuy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will TriSalus Life Sciences Inc. stock gain from government policiesWeekly Market Summary & AI Enhanced Trading Signals - newser.com
Can TriSalus Life Sciences Inc. stock surprise with earnings upsideQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Is TriSalus Life Sciences Inc. Equity Warrant stock a safe haven assetMarket Rally & Safe Entry Trade Reports - newser.com
Will TriSalus Life Sciences Inc. stock attract more institutional investorsJuly 2025 Snapshot & Safe Capital Investment Plans - newser.com
Is now a turning point for TriSalus Life Sciences Inc. Equity WarrantQuarterly Portfolio Report & Real-Time Volume Analysis - newser.com
Is TriSalus Life Sciences Inc. Equity Warrant stock overvalued by current metrics2025 Market Overview & Precise Buy Zone Tips - newser.com
What’s next for TriSalus Life Sciences Inc. stock price2025 Technical Overview & Community Consensus Picks - newser.com
Ranking TriSalus Life Sciences Inc. Equity Warrant among high performing stocks via toolsWeekly Stock Recap & Precise Entry and Exit Recommendations - newser.com
Does TriSalus Life Sciences Inc. show high probability of rebound2025 EndofYear Setup & Technical Confirmation Alerts - newser.com
Will TriSalus Life Sciences Inc. stock gain from strong economyEarnings Growth Summary & Daily Entry Point Trade Alerts - newser.com
Will breakout in TriSalus Life Sciences Inc. Equity Warrant lead to full recoverySwing Trade & Technical Pattern Based Buy Signals - newser.com
Custom strategy builders for tracking TriSalus Life Sciences Inc.2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
How resilient is TriSalus Life Sciences Inc. Equity Warrant stock in market downturns2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Can machine learning forecast TriSalus Life Sciences Inc. Equity Warrant recoveryJuly 2025 Patterns & AI Forecast Swing Trade Picks - newser.com
Regression analysis insights on TriSalus Life Sciences Inc. Equity Warrant performance2025 Fundamental Recap & AI Driven Stock Reports - newser.com
What high frequency data says about TriSalus Life Sciences Inc. Equity WarrantAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Combining price and volume data for TriSalus Life Sciences Inc.2025 Growth vs Value & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-10-31 03:21:25 - newser.com
Published on: 2025-10-31 01:48:31 - newser.com
Published on: 2025-10-31 01:24:13 - newser.com
What high frequency data says about TriSalus Life Sciences Inc.GDP Growth & Weekly Market Pulse Alerts - newser.com
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.06%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):